$28M Philly Xarelto Verdict Ripe For Reversal, Attys Say

Law360, Philadelphia (December 6, 2017, 6:27 PM EST) -- After three prior bellwether trial losses, plaintiffs in litigation over the anticoagulant Xarelto are hoping to gain momentum following a $27.8 million verdict in Philadelphia on Tuesday, but attorneys say the award faces an uncertain future thanks to testimony that additional warnings would not have changed a doctor's decision to prescribe the drug.

The verdict against a pair of Johnson & Johnson and Bayer AG units, which included $26 million in punitive damages, came despite testimony from plaintiff Lynn Hartman's physician that additional warnings about the drug's risks of internal bleeding would not have changed her prescribing decision.

Such testimony, attorneys...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!